Clinical trial
A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination…
NCT00337376 · Yale University, Other · Terminated
Key facts
| NCT number | NCT00337376 |
|---|---|
| Title | A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers |
| Official title | A Phase I Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane (Paclitaxel Protein-bound Particles) in Advanced Solid Cancers |
| Lead sponsor | Yale University, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Solid Cancers |
| Intervention type | Drug |
| Interventions | Rapamune, Abraxane |
| Enrollment | 23 |
| Start date | Feb 1, 2006 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Jun 15, 2006 |
| Last update posted | Jan 14, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: